First-in-Class Immune / Transcription Modulators Targeting p-STAT3

WP1066 is our flagship Immune/Transcription Modulator. It has been the subject of over 50 peer-reviewed articles and its activity against p-STAT3 has now been validated in independent laboratories around the globe. This breakthrough discovery was made by our Scientific Founder, Dr. Waldemar Priebe, at The University of Texas MD Anderson Cancer Center.

WP1066 has shown significant anti-tumor activity in a wide range of tumor cell lines and increased survival in a number of animal models, and this activity has been validated in multiple independent laboratories in different institutions worldwide.

U.S. FDA Rare Pediatric Disease Designation (RPD) for four different forms of pediatric brain tumors

Target Indications:

Glioblastoma (GBM) Brain Tumors

Pediatric Brain Tumors, Including DIPG


Our Clinical Studies

Sign Up For Alerts